pentetic acid has been researched along with Carcinoma, Neuroendocrine in 11 studies
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medullary thyroid cancer (MTC) is a rare but potentially life-threatening disease with limited therapeutic options." | 2.80 | Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? ( Bulzico, DA; Carneiro, M; Corbo, R; de Carvalho Leal, D; Kendler, DB; Lopes, FP; Pessoa, CH; Rosado de Castro, PH; Vaisman, F; Vaisman, M; Vilhena, B, 2015) |
| " Maximal potassium levels were within the toxic range (6." | 2.71 | Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. ( de Jong, M; Kooij, PP; Krenning, EP; Rolleman, EJ; Valkema, R, 2003) |
| "A 51-year-old woman was found to have a recurrence 23 months after laparoscopic distal pancreatectomy, splenectomy and wedge resection of a liver metastasis for a non-functional neuroendocirne neoplasm of the pancreas." | 1.35 | Intraoperative hand held gamma probe detection of a recurrent nonfunctional neuroendocrine tumor. ( Fitzgerald, TL; Van Haren, RM, 2008) |
| "Some breast tumors are classified as primary neuroendocrine carcinomas because of argyrophilia and positivity for neuroendocrine markers (chromogranins A and B and neuron-specific enolase), regardless of their cellular rest and cord structures." | 1.31 | Tc-99m sestamibi and In-111 DTPA octreotide uptake in breast carcinoma with neurendocrine differentiation. ( D'Eredità, G; Rubini, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beukhof, CM | 1 |
| Brabander, T | 1 |
| van Nederveen, FH | 1 |
| van Velthuysen, MF | 1 |
| de Rijke, YB | 1 |
| Hofland, LJ | 1 |
| Franssen, GJH | 1 |
| Fröberg, LAC | 1 |
| Kam, BLR | 1 |
| Visser, WE | 1 |
| de Herder, WW | 1 |
| Peeters, RP | 1 |
| Vaisman, F | 1 |
| Rosado de Castro, PH | 1 |
| Lopes, FP | 1 |
| Kendler, DB | 1 |
| Pessoa, CH | 1 |
| Bulzico, DA | 1 |
| de Carvalho Leal, D | 1 |
| Vilhena, B | 1 |
| Vaisman, M | 1 |
| Carneiro, M | 1 |
| Corbo, R | 1 |
| Van Haren, RM | 1 |
| Fitzgerald, TL | 1 |
| Bomanji, JB | 1 |
| Papathanasiou, ND | 1 |
| Salaun, PY | 1 |
| Campion, L | 1 |
| Bournaud, C | 1 |
| Faivre-Chauvet, A | 1 |
| Vuillez, JP | 1 |
| Taieb, D | 1 |
| Ansquer, C | 1 |
| Rousseau, C | 1 |
| Borson-Chazot, F | 1 |
| Bardet, S | 1 |
| Oudoux, A | 1 |
| Cariou, B | 1 |
| Mirallié, E | 1 |
| Chang, CH | 1 |
| Sharkey, RM | 1 |
| Goldenberg, DM | 1 |
| Chatal, JF | 1 |
| Barbet, J | 1 |
| Kraeber-Bodéré, F | 1 |
| Boubaker, A | 1 |
| Prior, JO | 1 |
| Willi, JP | 1 |
| Champendal, M | 1 |
| Kosinski, M | 1 |
| Bischof Delaloye, A | 1 |
| Maecke, HR | 1 |
| Ginj, M | 1 |
| Baechler, S | 1 |
| Buchegger, F | 1 |
| Rolleman, EJ | 1 |
| Valkema, R | 2 |
| de Jong, M | 2 |
| Kooij, PP | 1 |
| Krenning, EP | 2 |
| Teunissen, JJ | 1 |
| Kwekkeboom, DJ | 1 |
| Esser, JP | 1 |
| Imperiale, A | 1 |
| Blondet, C | 1 |
| Choquet, P | 1 |
| Constantinesco, A | 1 |
| Oliaro, A | 1 |
| Filosso, PL | 1 |
| Bello, M | 1 |
| Casadio, C | 1 |
| Muni, A | 1 |
| Greco, B | 1 |
| Bertuccio, G | 1 |
| Bisi, G | 1 |
| Maggi, G | 1 |
| Rubini, G | 1 |
| D'Eredità, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors[NCT04790708] | 250 participants (Anticipated) | Interventional | 2018-07-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pentetic acid and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Topics: 3-Iodobenzylguanidine; Carcinoid Tumor; Carcinoma, Neuroendocrine; Humans; Iodine Radioisotopes; Neu | 2012 |
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Luteti | 2005 |
3 trials available for pentetic acid and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Octreotide; Organometalli | 2015 |
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; | 2012 |
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
Topics: Arginine; Carcinoma, Neuroendocrine; Female; Humans; Hyperkalemia; Infusions, Intravenous; Kidney; L | 2003 |
6 other studies available for pentetic acid and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Feasibility Studies; Female; Humans; Male; Middle Aged; Octr | 2019 |
Intraoperative hand held gamma probe detection of a recurrent nonfunctional neuroendocrine tumor.
Topics: Carcinoma, Neuroendocrine; Female; Gamma Rays; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle | 2008 |
Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Oc | 2012 |
In-111 DTPA-D-Phe1-octreotide SPECT in a rare case of anorectal small-cell undifferentiated neuroendocrine carcinoma.
Topics: Aged; Anus Neoplasms; Carcinoma, Neuroendocrine; Female; Humans; Octreotide; Pentetic Acid; Radiopha | 2006 |
Neuroendocrine carcinomas of the lung and role of 111In-DTPA-octreotide scintigraphy: preliminary results.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; | 1996 |
Tc-99m sestamibi and In-111 DTPA octreotide uptake in breast carcinoma with neurendocrine differentiation.
Topics: Aged; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Human | 2000 |